Article

Macular edema device coming to Japan

Irvine, CA—Allergan Inc. has signed an exclusive licensing agreement with Japan's Sanwa Kagaku Kenkyusho Co. Ltd. to develop and commercialize Posurdex for the ophthalmic marketplace in that country.

Irvine, CA-Allergan Inc. has signed an exclusive licensing agreement with Japan's Sanwa Kagaku Kenkyusho Co. Ltd. to develop and commercialize Posurdex for the ophthalmic marketplace in that country.

The investigational, bioerodable, extended release implant is designed to deliver dexamethasone to the back of the eye to treat macular edema. The companies estimate Japan's annual macular edema market at more than $100 million.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
© 2025 MJH Life Sciences

All rights reserved.